Return to Listing

9 result(s) for Other Hematologic Malignancy

PI Name Protocol # Title
Richard Maziarz IRB00009375 A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT
Emma Scott IRB00009421 A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Richard Maziarz IRB00009585 Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
Kim-Hien Dao IRB00010262 Prospective Evaluation of ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R
Kim-Hien Dao IRB00010849 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Richard Maziarz IRB00010941 A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
Emma Scott IRB00011097 A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients with Relapsed High-Risk Multiple Myeloma
Kevin Yee IRB00011213 Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices (REVEAL)
Stephen Spurgeon IRB00011311 A Phase 1/2 Proof-of-concept study of the combination of ACP-196 and ACP-319 in subjects with B-cell malignancies
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080